BSX vs DCTH
BSX: Boston Scientific is a leading medical device company dedicated to transforming lives through innovative, less-invasive medical solutions for a broad range of interventional specialties. DCTH: Delcath Systems is an interventional oncology company providing a proprietary drug/device combination for liver-directed cancer treatment.
Side-by-side fundamentals
| Metric | BSX | DCTH | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $45.58 | $14.76 | |
| Market cap | $66.1B | $512M | |
| P/E as of 2026-10-20 | 18.45 | n/a | |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2025 | 0.29 | n/a | |
| Net margin FY2025, SEC XBRL | +14.4% | +3.2% | BSX higher |
| Gross margin FY2025, SEC XBRL | +69.0% | +86.2% | DCTH higher |
| Operating margin FY2025, SEC XBRL | +18.0% | +0.8% | BSX higher |
| ROE FY2025, SEC XBRL | +11.8% | +2.4% | BSX higher |
| ROA FY2025, SEC XBRL | +6.6% | +2.2% | BSX higher |
| Debt / equity filed borrowings incl. finance leases, balance sheet 2026-06-30 | 0.51 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +19.9% | +129.1% | DCTH higher |
| Revenue CAGR (3y) SEC XBRL | +16.5% | +215.3% | DCTH higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.57 | 1.37 | |
| 1-year return as of 2026-10-20 close | -54.7% | +29.2% | DCTH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.